Defining the genetic aetiology of monogenic diabetes can improve treatment

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 13, 2006, Pages 1759-1767

  Gloyn, Anna L ^c   Ellard, Sian ^a,b  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c NONE

Author keywords

Diabetes; Glucokinase; Insulin; Kir6.2; Maturity onset diabetes of the young; Monogenic; Neonatal diabetes; Sulphonylureas

Indexed keywords

INSULIN;

ANIMAL; DIABETES MELLITUS; DISEASE COURSE; GENETICS; HUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; REVIEW; SECRETION;

AGE OF ONSET; ANIMALS; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; INSULIN; INSULIN-SECRETING CELLS;

EID: 33847404628     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.13.1759     Document Type: Review

References (64)

1. TATTERSALL RB: Mild familial diabetes with dominant inheritance. QJ Med. (1974) 43:339-357.
2. FROGUEL P, VAXILLAIRE M, SUN F et al.: Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature (1992) 356:162-164.
3. HATTERSLEY AT, TURNER RC, PERMUTT MA et al.: Linkage of type 2 diabetes to the glucokinase gene. Lancet (1992) 339:1307-1310.
4. GLOYN AL: Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinaemia of infancy. Hum. Mutat. (2003) 22(5):353-362. •• Review of all the published mutations and polymorphisms in the glucokinase gene with a summary of clinical phenotypes and implications for therapy.
5. FRAYLING TM, EVANS JC, BULMAN MP et al.: Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes (2001) 50(Suppl. 1):S94-S100. (Pubitemid 32148228)
6. STRIDE A, VAXILLAIRE M, TUOMI T et al.: The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia (2002) 45(3):427-435. • Paper describing a large European series of cases of MODY giving detailed clinical characteristics of GCK-MODY and HNF1A-MODY.
7. VAXILLAIRE M, BOCCIO V, PHILIPPI A et al.: A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. Nat. Genet. (1995) 9(4):418-423.
8. YAMAGATA K, ODA N, KAISAKI PJ et al.: Mutations in the hepatic nuclear factor 1 alpha gene in maturity-onset diabetes of the young (MODY3). Nature (1996) 384:455-458. (Pubitemid 26414660)
9. BELL GI, XIANG KS, NEWMAN MV: Gene for non-insulin dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc. Natl Acad. Sci. USA (1991) 88:1484-1488. (Pubitemid 21916249)
10. YAMAGATA K, FURUTA H, ODA N et al.: Mutations in the hepatocyte nuclear factor 4 alpha gene in maturity-onset diabetes of the young (MODY1). Nature (1996) 384:458-460. (Pubitemid 26414661)
11. ELLARD S, COLCLOUGH K: Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF-1) and 4 alpha (HNF-4) in maturity-onset diabetes of the young. Hum. Mutat. (2006) 27:854-869. •• Details of all published mutations and polymorphisms in both the HNF1A and HNF4A genes. Detailed description of the clinical phenotype and implications for treatment. (Pubitemid 44336935)
12. NISHIGORI H, YAMADA S, KOHAMA T et al.: Frameshift mutation, A263fsinsGG, in the hepatocyte nuclear factor-1 beta gene associated with diabetes and renal dysfunction. Diabetes (1998) 47(8):1354-1355. (Pubitemid 28357016)
13. BEARDS F, FRAYLING T, BULMAN M et al.: Mutations in hepatocyte nuclear factor 1 beta are not a common cause of maturity-onset diabetes of the young in the U.K. Diabetes (1998) 47:1152-1154. (Pubitemid 28294560)
14. BINGHAM C, BULMAN M, ELLARD S et al.: Mutations in the HNF1-beta gene are associated with familial hypoplastic glomerulocystic kidney disease. Am. J. Hum. Genet. (2001) 68:219-224. (Pubitemid 32048377)
15. BINGHAM C, ELLARD S, ALLEN L et al.: Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1 beta. Kidney Int. (2000) 57(3):898-907. (Pubitemid 30434780)
16. EDGHILL EL, BINGHAM C, ELLARD S, HATTERSLEY AT: Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J. Med. Genet. (2006) 43(1):84-90. (Pubitemid 43099997)
17. BRACKENRIDGE A, PEARSON ER, SHOJAEE-MORADIE F et al.: Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1beta and -1alpha mutations. Diabetes (2006) 55(2):405-411. (Pubitemid 43343270)
18. STOFFERS DA, FERRER J, CLARKE WL, HABENER JF: Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. (1997) 17:138-139.
19. STOFFERS DA, ZINKIN NT, STANOJEVIC V, CLARKE WL, HABENER JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat. Genet. (1997) 15:106-110. (Pubitemid 27014961)
20. CHÈVRE JC, HANI EH, STOFFERS A, HABENER JF, FROGUEL P: Insulin Promoter Factor 1 gene (IPF1) is not a major cause of maturity-onset diabetes of the young in French Caucasians. Diabetes (1998) 47:843-844. (Pubitemid 28201818)
21. HARA M, LINDNER TH, PAZ VP et al.: Mutations in the coding region of the insulin promoter factor 1 gene are not a common cause of maturity-onset diabetes of the young in Japanese subjects. Diabetes (1998) 47:845-846. (Pubitemid 28201819)
22. MALECKI MT, JHALA US, ANTONELLIS A et al.: Mutations in NEUROD1 are associated with the development of Type 2 diabetes mellitus. Nat. Genet. (1999) 23(3):323-328. (Pubitemid 29526431)
23. KRISTINSSON SY, THOROLFSDOTTIR ET, TALSETH B et al.: MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in NeuroD1. Diabetologia (2001) 44(11):2098-2103. (Pubitemid 33124057)
24. RAEDER H, JOHANSSON S, HOLM PI et al.: Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet. (2006) 38(1):54-62. (Pubitemid 43011882)
25. SCHNYDER S, MULLIS PE, ELLARD S, HATTERSLEY AT, FLUCK CE: Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment. Swiss Med. Wkly (2005) 135(23-24):352-356. •• Paper reporting the benefits of diagnostic testing in GCK-MODY.
26. SPYER G, HATTERSLEY AT, SYKES JE, STURLEY RH, MACLEOD KM: Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am. J. Obstet. Gynecol. (2001) 185(1):240-241. (Pubitemid 32681826)
27. PEARSON ER, LIDDELL WG, SHEPHERD M, CORRALL RJ, HATTERSLEY AT: Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor 1 alpha gene mutations: evidence for pharmacogenetics in diabetes. Diab Med (2000) 17:543-545. (Pubitemid 30660158)
28. PEARSON ER, STARKEY BJ, POWELL RJ et al.: Genetic aetiology of hyperglycaemia determines response to treatment in diabetes. Lancet (2003) 362(9392):1275-1281. •• First study to show pharmacogenetics in diabetes. A randomised case-controlled study in HNF1A-MODY.
29. PEARSON ER, PRUHOVA S, TACK CJ et al.: Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia (2005) 48(5):878-885. (Pubitemid 40767980)
30. SHEPHERD M, PEARSON ER, HOUGHTON J et al.: No deterioration in glycaemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care (2003) 26(11):3191-3192. •• Reports the results of transferring patients with HNF1A-MODY from insulin to sulphonylureas. (Pubitemid 37339526)
31. SHEPHERD M, HATTERSLEY AT: 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Clin. Med. (2004) 4(2):144-147. • Reports the improvements in quality of life in patients with HNF1A-MODY after successful transfer from insulin injections to oral sulphonylureas. (Pubitemid 39060809)
32. MASSA O, IAFUSCO D, D'AMATO E et al.: KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum. Mutat. (2004) 25(1):22-27.
33. IAFUSCO D, STAZI MA, COTICHINI R et al.: Permanent diabetes mellitus in the first year of life. Diabetologia (2002) 45(6):798-804.
34. EDGHILL EL, DIX R, FLANAGAN SE et al.: HLA genotyping supports a non-autoimmune aetiology in patients diagnosed with diabetes under the age of 6 months. Diabetes (2006) 55(6):1895-11890 (Pubitemid 44324150)
35. TEMPLE IK, GARDNER RJ, MACKAY DJ et al.: Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes (2000) 49(8):1359-1366. (Pubitemid 30624238)
36. DELEPINE M, NICOLINO M, BARRETT T et al.: EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. (2000) 25(4):406-409. (Pubitemid 32983431)
37. WILDIN RS, RAMSDELL F, PEAKE J et al.: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. (2001) 27(1):18-20. (Pubitemid 32044512)
38. SELLICK GS, BARKER KT, STOLTE-DIJKSTRA I et al.: Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat. Genet. (2004) 36(12):1301-1305. (Pubitemid 39577939)
39. NJOLSTAD P, SOVIK O, CUESTA-MUNOZ A et al.: Neonatal diabetes mellitus due to complete glucokinase deficiency. New Engl. J. Med. (2001) 344:1588-1592. (Pubitemid 32479911)
40. NJOLSTAD PR, SAGEN JV, BJORKHAUG L et al.: Permanent neonatal diabetes mellitus due to glucokinase deficiency- an inborn error of glucose-insulin signalling pathway. Diabetes (2003) 52(11):2854-2860. (Pubitemid 37339717)
41. PORTER JR, SHAW NJ, BARRETT TG et al.: Permanent neonatal diabetes in an Asian infant. J. Pediatr. (2005) 146(1):131-133. (Pubitemid 40091744)
42. GLOYN AL, ELLARD S, SHIELD JP et al.: Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia (2002) 45(2):290. (Pubitemid 34208395)
43. VAXILLAIRE M, SAMSON C, CAVE H et al.: Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia (2002) 45(3):454-455. (Pubitemid 34267372)
44. GLOYN A, ODILI S, BUETTGER C et al.: Glucokinase and the regulation of blood sugar: a mathematical model predicts the threshold for glucose stimulated insulin release for GCK gene mutations that cause hyper- and hypoglycaemia. In Glucokinase and Glycaemic Diseases: From the Basics to Novel Therapeutics. Matschinsky FM, Magnuson MA (Eds) Karger (2004):92-109.
45. THOMAS PM, COTE GJ, WOHILK N et al.: Mutations in the sulphonylurea receptor and familial persistent hyperinsulinaemic hypoglycemia of infancy. Science (1995) 268:426-429.
46. THOMAS PM, YUYANG Y, LIGHTNER E: Mutation of the pancreatic islet inward rectifier, Kir6.2 also leads to familial persistent hyperinsulinaemic hypoglycemia of infancy. Hum. Mol. Genet. (1996) 5:1809-1812. (Pubitemid 26372418)
47. KOSTER JC, MARSHALL BA, ENSOR N, CORBETT JA, NICHOLS CG: Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell (2000) 100(6):645-654.
48. GLOYN AL, PEARSON ER, ANTCLIFF JF et al.: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. (2004) 350(18):1838-1849. • First report of the identification of KCNJ11 mutations as a common genetic aetiology for PNDM. First demonstration that patients may respond to sulphonylureas.
49. SAGEN JV, RAEDER H, HATHOUT E et al.: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes (2004) 53:2713-2718. • First demonstration that patients can be treated with oral sulphonylureas. (Pubitemid 39299284)
50. VAXILLAIRE M, POPULAIRE C, BUISIAH K et al.: Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes (2004) 53:2719-2722. (Pubitemid 39299285)
51. FLANAGAN SE, EDGHILL EL, GLOYN AL, ELLARD S, HATTERSLEY AT: Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia (2006) 49(6):1190-1197.
52. HATTERSLEY AT, ASHCROFT FM: Activating mutations in kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes (2005) 54(9):2503-2513. (Pubitemid 41233571)
53. GLOYN AL, DIATLOFF-ZITO C, EDGHILL EL et al.: KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur. J. Hum. Genet. (2006) 14(7):824-830. (Pubitemid 43923367)
54. SAKURA H, AMMALA C, SMITH PA, GRIBBLE FM, ASHCROFT FM: Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. FEBS Lett. (1995) 377:338-344. (Pubitemid 26025723)
55. PROKS P, ANTCLIFF JF, LIPPIAT J et al.: Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc. Natl Acad. Sci. USA (2004) 101(50):17539-17544. (Pubitemid 39657439)
56. PROKS P, GIRARD C, HAIDER S et al.: A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep. (2005) 6(5):470-475. (Pubitemid 40767081)
57. PROKS P, GIRARD C, ASHCROFT FM: Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP. Hum. Mol. Genet. (2005) 14(18):2717-2726. (Pubitemid 41300644)
58. PROKS P, ARNOLD A, BRUINING J et al.: A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum. Mol. Genet. (2006) 15(11):1793-1800. • First description of a mutation in ABCC8 resulting in DEND syndrome.
59. GLOYN AL, REIMANN F, GIRARD C et al.: Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum. Mol. Genet. (2005) 14(7):925-934. (Pubitemid 40533103)
60. SEINO S, IWANAGA T, NAGASHIMA K, MIKI T: Diverse roles of K-ATP channels learned from Kir6.2 genetically engineered mice. Diabetes (2000) 49(3):311-318. (Pubitemid 30131774)
61. ZUNG A, GLASER B, NIMRI R, ZADIK Z: Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J. Clin. Endocrinol. Metab. (2004) 89(11):5504-5507. (Pubitemid 39518433)
62. CODNER E, FLANAGAN S, ELLARD S, GARCIA H, HATTERSLEY AT: High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care (2005) 28(3):758-759. (Pubitemid 40315352)
63. KLUPA T, EDGHILL EL, NAZIM J et al.: The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia (2005) 48(5):1029-1031. (Pubitemid 40767999)
64. PEARSON E, R FLECHTNER I, NJØLSTÅD P et al.: The successful transfer of insulin treated patients with diabetes due to Kir6.2 (KCNJ11) mutations to oral sulphonylureas. New Engl. J. Med. (2006) 355(5):467-477. •• The results from a large cohort of subjects with KCNJ11 mutations who have been successfully transferred from insulin injections to oral sulphonylurea tablets.